Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.

Metabolic syndrome (MS), defined as central obesity, hyperinsulinemia, insulin resistance, hypertension, dyslipidemia and glucose intolerance, has been associated with inflammatory biomarkers and cardiovascular diseases. This study was carried out on three groups of women; lean controls, moderately obese with MS (OB-MS) and morbidly obese with MS (MOB-MS). The main objectives were: 1. to analyze the plasma levels of total and acylated ghrelin, peptide YY(3-36) (PYY(3-36)), cholecystokinin (CCK), gastrin and insulin levels under basal conditions and in response to a standard mixed meal, and 2. to elucidate the relationship between the plasma levels of these gut peptides and metabolic syndrome parameters. Plasma levels of the gut hormones were measured by radioimmunoassays at time 0 just before the meal and at 30, 60 and 120 min after a meal ingestion. Traditional lipid profile and high-sensitivity C reactive protein (hs-CRP), the strongest biomarker of inflammation were also determined in OB-MS and MOB-MS. When compared to OB-MS, MOB-MS exhibited much higher anthropometric parameters such as waist circumference, higher fat mass and higher plasma levels of low density lipoprotein-cholesterol (LDL-C) and hs-CRP. Both these obese groups revealed significantly higher values of body mass index (BMI), fat mass, total cholesterol (TC), LDL-C, fasting glucose, fasting insulin, insulin resistance (IR) calculated from homeostatic model assessment (HOMA) and hs-CRP compared to the values recorded in lean subjects. Fasting PYY(3-36) level was lower, while fasting acylated ghrelin was higher in MOB-MS than in OB-MS. Plasma total and acylated ghrelin levels were significantly lower in OB-MS compared to lean women. In MOB-MS women the fasting PYY(3-36) levels were lower compared to lean controls and OB-MS, whilst postprandially in both OB-MS and MOB-MS, it was much lower than in lean women. The fasting plasma levels of total and acylated ghrelin and their postprandial decrease were significantly smaller in both obese groups compared to lean subjects. Plasma hs-CRP levels correlated positively with BMI, waist circumference, fat mass, fasting glucose, HOMA IR and fasting active ghrelin, whilst it negatively correlated with plasma fasting and total ghrelin. Moreover, plasma fasting acylated ghrelin correlated positively with fat mass. Fasting total ghrelin correlated positively with BMI, HDL-C and negatively with HOMA IR. We conclude that MS features of obesity are closely related to fasting and postprandial alterations of concentrations of PYY(3-36), CCK and ghrelin, suggesting that determination of gut hormones controlling food intake might be considered as a valuable tool to assess the progression of MS to comorbidities of obesity.

[1]  J. H. Peters,et al.  Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin , 2006, Physiology & Behavior.

[2]  Norbert Bannert,et al.  Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats , 2006, Brain Research.

[3]  D. Cummings Ghrelin and the short- and long-term regulation of appetite and body weight , 2006, Physiology & Behavior.

[4]  Jia-Yi Li,et al.  Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats , 2006, British journal of pharmacology.

[5]  M. Päivänsalo,et al.  Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males , 2006, Journal of internal medicine.

[6]  P. Holvoet,et al.  Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Y. Dong,et al.  Regulative effects of ovarian steroids on rat gastric motility and sensitivity. , 2006, Sheng li xue bao : [Acta physiologica Sinica].

[8]  M. Jensen Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors , 2006, Obesity.

[9]  U. Müller-Ladner,et al.  Role of adipose tissue as an inflammatory organ in human diseases. , 2006, Endocrine reviews.

[10]  J. Rehfeld The endoproteolytic maturation of progastrin and procholecystokinin , 2006, Journal of Molecular Medicine.

[11]  J. Meigs Definitions and mechanisms of the metabolic syndrome , 2006 .

[12]  J. Wishart,et al.  Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  L. Lind,et al.  Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study , 2006, BMJ : British Medical Journal.

[14]  Paul Poirier,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism , 2006, Circulation.

[15]  J. Olefsky,et al.  Inflamed fat: what starts the fire? , 2005, The Journal of clinical investigation.

[16]  P. Konturek,et al.  Neuro-hormonal control of food intake: basic mechanisms and clinical implications. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[17]  M. Wylezol,et al.  Bariatric surgery in Poland from 1993 to 2003. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[18]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[19]  Christoph Beglinger,et al.  Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.

[20]  D. Allison,et al.  PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[21]  T. Peeters,et al.  Ghrelin: a new player in the control of gastrointestinal functions , 2005, Gut.

[22]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[23]  S. Bloom,et al.  Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  G. Pacini,et al.  Islet adaptation to insulin resistance: mechanisms and implications for intervention , 2005, Diabetes, obesity & metabolism.

[25]  M. Nakazato,et al.  Altered ghrelin and peptide YY responses to meals in bulimia nervosa , 2005, Clinical endocrinology.

[26]  M. Fujimiya,et al.  Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin , 2004, Gut.

[27]  R. Ahima,et al.  Gut peptides and other regulators in obesity. , 2004, Seminars in liver disease.

[28]  B. Draznin,et al.  Molecular mechanisms of insulin resistance that impact cardiovascular biology. , 2004, Diabetes.

[29]  E. Arvat,et al.  Ghrelin secretion is inhibited by glucose load and insulin‐induced hypoglycaemia but unaffected by glucagon and arginine in humans , 2004, Clinical endocrinology.

[30]  R. Silverstein,et al.  Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. , 2004, The Biochemical journal.

[31]  H. Pijl,et al.  PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. , 2004, Diabetes.

[32]  K. Wynne,et al.  Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[33]  M. Korbonits,et al.  Ghrelin—a hormone with multiple functions , 2004, Frontiers in Neuroendocrinology.

[34]  J. Konturek,et al.  Brain-gut axis and its role in the control of food intake. , 2004, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[35]  B. Beck,et al.  Ghrelin and Body Weight Regulation in the Obese Zucker Rat in Relation to Feeding State and Dark/Light Cycle , 2003, Experimental biology and medicine.

[36]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[37]  K. Nin,et al.  Plasma levels of active form of ghrelin during oral glucose tolerance test in patients with anorexia nervosa. , 2003, European journal of endocrinology.

[38]  E. Ford The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. , 2003, Atherosclerosis.

[39]  C. Ronchi,et al.  Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. , 2003, The Journal of clinical endocrinology and metabolism.

[40]  R. Jensen,et al.  Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. , 2002, Pharmacology & toxicology.

[41]  K. Kangawa,et al.  Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. , 2002, Diabetes.

[42]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[43]  J. Yudkin,et al.  The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome—an analysis by structural equation modelling , 2002, International Journal of Obesity.

[44]  Márta Korbonits,et al.  The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[45]  S. Bloom,et al.  Food fails to suppress ghrelin levels in obese humans. , 2002, The Journal of clinical endocrinology and metabolism.

[46]  J. A. Fernández-Represa,et al.  Peptide YY Secretion in Morbidly Obese Patients Before and After Vertical Banded Gastroplasty , 2002, Obesity surgery.

[47]  G. Schwartz,et al.  Responsivity to NPY and melanocortins in obese OLETF rats lacking CCK-A receptors , 2002, Physiology & Behavior.

[48]  M. Mulholland,et al.  Inhibition of pancreatic protein secretion by ghrelin in the rat , 2001, The Journal of physiology.

[49]  T. Koh,et al.  Gastrin as a growth factor in the gastrointestinal tract , 2000, Regulatory Peptides.

[50]  C. Beglinger,et al.  Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.

[51]  T. Brewerton,et al.  CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. , 1993, The American journal of psychiatry.

[52]  N. Read,et al.  Preliminary studies on the gastrointestinal responses to fatty meals in obese people. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[53]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[54]  J. H. Payne,et al.  Surgical treatment of obesity. , 1969, American journal of surgery.

[55]  K. Wynne,et al.  Attenuated peptide YY release in obese subjects is associated with reduced satiety. , 2006, Endocrinology.

[56]  G. Dockray,et al.  Gastrin: old hormone, new functions , 2004, Pflügers Archiv.

[57]  C. Dina,et al.  Genetic, pharmacological and functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor polymorphism in type 2 diabetes and obese patients. , 2002, Pharmacogenetics.